About Helomics
Helomics is a Healthcare company based in Pittsburgh (United States) founded in 1995. Targeted cancer therapies are developed via an AI-driven platform. Helomics has raised $195.59 million across 9 funding rounds from investors including Predictive Oncology, Draper Triangle and HealthCare Royalty Partners. The company has 13 employees. The company has since been acquired. Helomics offers products and services including AI/ML Platform, 3D Tumor Models, and ChemoFx Testing. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Precision Medicine. Its competitors include Denali Therapeutics, C4 Therapeutics and Erasca; 3 of its 3 listed competitors have raised funding.
Company details
Helomics was established in 1995 in Pittsburgh, United States, within the biotechnology sector focused on oncology. An AI-driven platform is operated to create targeted therapies for cancer patients. Proprietary technology and data pipelines are maintained to deliver services to pharmaceutical and diagnostic firms, supporting the advancement of precision medicine solutions in the region.
- Headquarters Pittsburgh, United States
- Employees 13
- Stage Acquired
- SectorsHealthcare
- Website helomics.com
- Social LinkedIn X Facebook
- Acquired by Predictive Oncology (Jun 2018)
- Total Equity Funding$195.59M (USD)
in 9 rounds
- Latest Funding Round$3M (USD), Series E
Apr 2018
- InvestorsPredictive Oncology
& 11 more
- Employee Count13
Products & Services of Helomics
Helomics offers a comprehensive portfolio of products and services, including AI/ML Platform, 3D Tumor Models, and ChemoFx Testing.
Platform predicts drug responses using tumor samples and machine learning.
Models mimic patient responses for oncology drug development testing.
Service for tumor drug-response and genomic biomarker analysis.
Funding Insights of Helomics
Helomics has successfully raised a total of $195.59M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $3 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $195.59M
- Total Rounds 9
- Last Round Series E β $3M
- First Round $17.5M
(Nov 2001)
- Investors Count 11
All 9 funding rounds of Helomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2018 | $3M | Series E | β | β | β |
| Jun 2017 | $110,000 | Series E | β | β | β |
| Mar 2017 | $1.98M | Series E | β | β | β |
| Nov 2014 | $60M | Series E | β | β | |
| Jun 2010 | $35M | Series D | β | Bain Capital Ventures | |
| Nov 2008 | $43M | Series D | β | β | |
| Feb 2006 | $20M | Series C | β | β | |
| Sep 2003 | $15M | Series C | β | β | |
| Nov 2001 | $17.5M | Series B | β | β |
12 investors in total: 12 institutional.
Investors in Helomics
Helomics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Predictive Oncology, Draper Triangle and HealthCare Royalty Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare royalty investments are focused on US and UK markets. | healthcareroyalty.com | Stamford, United States | ||
Early-stage VC investments are made in US tech companies. | acm.com | Sewickley, United States | ||
US focused early-stage VC firm investing in tech & life sciences start-ups | birchmerevc.com | Pittsburgh, United States | ||
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
US focused early stage VC investments company | 1999 | drapertriangle.com | Pittsburgh, United States | |
Capital is invested in life science innovations for healthcare transformation. | tvm-capital.com | Munich, Germany | ||
Private equity investments are managed via a family office structure. | hillmancompany.com | Pittsburgh, United States | ||
Venture capital fund focused on investing in multiple sectors | baincapitalventures.com | Boston, United States | ||
| quakerbio.com | ||||
| tvmvc.com |
Investor details for Helomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Helomics
4 dated milestones of Helomics across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Helomics is founded.
- Funding First funding round of $17.5M.
- Funding Latest funding round, Series E, of $3.0M.
- Exit Acquired by Predictive Oncology.
Competitors of Helomics
Helomics has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, C4 Therapeutics and Erasca.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. |
Detailed competitors of Helomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Helomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Helomics
Complete news archive for Helomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Helomics
Helomics was founded in 1995 and raised its 1st funding round 6 years after it was founded.
Helomics is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Helomics is a funded company, having raised a total of $195.59M across 9 funding rounds to date. The company's 1st funding round was a Series B of $17.5M, raised on Nov 2001.
Helomics has 13 employees.
Helomics was established in 1995 in Pittsburgh, United States, within the biotechnology sector focused on oncology. An AI-driven platform is operated to create targeted therapies for cancer patients. Proprietary technology and data pipelines are maintained to deliver services to pharmaceutical and diagnostic firms, supporting the advancement of precision medicine solutions in the region.
Helomics's top competitors include C4 Therapeutics, Erasca and Denali Therapeutics.
Helomics offers AI/ML Platform, 3D Tumor Models, and ChemoFx Testing.
Helomics has 12 investors. Key investors include Predictive Oncology, Draper Triangle, HealthCare Royalty Partners, Adams Capital Management, and Birchmere Ventures.
Yes. Helomics was acquired by Predictive Oncology in June 2018.